HOMA-IR: How to Calculate It and How to Interpret the Result

The most common mistake when calculating HOMA-IR by hand is mixing up units. Laboratories report glucose in mg/dl or mmol/l (1 mmol/l corresponds to about 18 mg/dl), and insulin in µIU/ml (or mIU/l — the same numerical value) or in pmol/l. The formula with 405 requires glucose in mg/dl, the formula with 22.5 requires mmol/l, and in both, insulin must be in µIU/ml. If the laboratory reports insulin in pmol/l, you must first convert it to µIU/ml by dividing by about 6.945 (1 µIU/ml corresponds to about 6.9 pmol/l; the literature also uses the approximation of 6.0, so with pmol/l always check which factor your calculator uses).

The HOMA model was described in 1985 by Matthews et al. It rests on a simple idea: when fasting, blood glucose and insulin concentrations result from a feedback loop between the liver, which produces glucose, and the pancreas, which secretes insulin. By comparing measured values with the predictions of a computer model, one can estimate how much of the deviation is due to tissue resistance to insulin and how much to inadequate beta-cell function. The simplified formulas (405 and 22.5) are an approximation of this model that is easy to compute on a calculator.

The 2004 review by Wallace, Levy and Matthews, written by the creators of the method, organizes its uses. It points out that HOMA is a widely used clinical and epidemiological tool, validated against various physiological methods, and that it has the advantage of requiring only a single plasma sample. The authors stress, however, that the result is reliable only when the input data are sound, and that the index works best in cohort and epidemiological studies rather than as a stand-alone measure of beta-cell function in isolation. For the patient, this means HOMA-IR is a good screening and comparison tool, but not a precise measurement.

It is also worth remembering what HOMA-IR measures and what it does not. It is based on the fasting state, so it reflects primarily insulin resistance of the liver, i.e. how easily insulin suppresses overnight glucose production, and not how effectively muscles take up glucose after a meal. A person with a normal HOMA-IR can therefore have glucose intolerance after a load, and vice versa. That is why, in unclear situations, doctors also reach for a glucose tolerance test.

Patients often look for an answer to the question 'above what value do I have insulin resistance'. The honest answer is: there is no single boundary common to everyone. In Polish laboratories and online descriptions, thresholds around 2.0–2.5 are most often seen (sometimes lower, e.g. 1.9, or higher, e.g. 2.9), but they come from different populations and methods, and studies show how strongly the result depends on how the cut-off is determined.

The same conclusion emerges from the review by Tahapary et al. (2022): there is high variability in the HOMA-IR thresholds used to define insulin resistance, and the distribution of the index depends on the characteristics of those studied, such as age, sex and race, which makes it hard to determine the optimal cut-off point. The authors add that a simpler alternative that does not require measuring insulin is the TyG index (from triglycerides and glucose), but for it too the thresholds vary. Transferring a boundary from one population (e.g. Spanish, Asian, American) to another without validation is therefore risky.

While glucose is measured with well-standardized methods, insulin measurement is much less consistent between laboratories. The report of an American Diabetes Association workgroup (Marcovina et al., 2007), which evaluated 12 commercial methods from 9 manufacturers, found that within-assay coefficients of variation ranged from 3.7% to 39.0%, and between different methods from 12% to 66% (median 24%). Using a common insulin reference preparation did not improve agreement between methods. Because insulin is one of the two variables in the HOMA-IR formula, its uncertainty is passed directly to the result of the index.

In practice this means that the same blood sample, tested by two different methods, can give insulin values differing by tens of percent, and therefore HOMA-IR by a similar amount. In addition, insulin is secreted in pulses, so even under the same conditions a single draw can vary. For these reasons, comparing HOMA-IR results from different laboratories is uncertain, and changes smaller than several tens of percent are hard to accept as real without repetition. With borderline results, it is most sensible to rely on two or more measurements taken in the same laboratory.

The gold standard for measuring insulin sensitivity is the hyperinsulinemic-euglycemic clamp, a research procedure in which insulin and glucose are given intravenously and the amount of glucose the body is able to use is measured. It is time-consuming and not routinely available, so surrogate indices are sought. The meta-analysis by Otten et al. (2014) gathered the correlations of such indices with the clamp. Among fasting-sample-based indices, the strongest correlations were for revised QUICKI (r=0.68), QUICKI (r=0.61), log HOMA-IR (r=−0.60) and HOMA-%S (r=0.57), and among those based on OGTT: Stumvoll MCR and OGIS (r=0.70), Matsuda (r=0.67), Stumvoll ISI (r=0.67) and Gutt (r=0.65).

There are two conclusions from this work. First, HOMA-IR (especially after logarithmic transformation) correlates moderately well with the clamp, at about 0.6, and does not differ markedly from other simple indices from a fasting sample. Second, OGTT-based indices are not clearly better than the best fasting-sample index. The authors judged revised QUICKI to be as good as the best OGTT measures and recommend it for large clinical studies. A correlation of about 0.6 means HOMA-IR explains roughly one-third of the variability in insulin sensitivity measured by the clamp, which shows the index is an approximation, not a precise measurement.

Several things follow for practice. HOMA-IR has real prognostic value, because people with higher values more often develop diabetes and hypertension and have non-fatal cardiovascular events. At the same time, these are observational studies, so they do not prove that the index itself is a cause, and the strength of the association (HR 1.3–1.9) is moderate. The lack of association with fatal cardiovascular events and cancer mortality in this meta-analysis warns against attributing a 'sentence' to a high HOMA-IR. It is a risk indicator that makes sense mainly alongside other factors.

A high HOMA-IR result is not a diagnosis, but a signal for a broader assessment. The first step is confirmation: repeating the test under the same conditions and at the same laboratory. The second is to put it alongside other data: waist circumference, body weight, blood pressure, lipid panel (triglycerides, HDL), fasting glucose, HbA1c, liver enzymes (fatty liver often coexists with insulin resistance), and in women symptoms of polycystic ovary syndrome. When the result is borderline or at odds with the clinical picture, the doctor may order a glucose tolerance test, in selected cases with insulin measurement.

Evidence for the benefits of lifestyle change comes mainly from studies of prediabetes: the review in The Lancet (Tabák et al., 2012) indicates that in people with prediabetes lifestyle interventions are associated with a 40–70% relative reduction in diabetes risk. It should be stressed, however, that these data concern the risk of diabetes, not the HOMA-IR index itself, which is only an indirect measure. There is no good evidence that lowering HOMA-IR in itself, independent of reducing visceral fat and improving fitness, translates into health benefits.

HOMA-IR is a tool that is easy to overrate and easy to dismiss. It is overrated when a result of 2.6 is treated as a diagnosis and 2.4 as health, forgetting the uncertainty of insulin assays and the lack of universal thresholds. It is dismissed when a high value is rejected just because glucose is normal, although that is precisely when the index makes the most sense: as an early signal that the body needs more insulin than it should. It is sensible to use it as one element of a broader assessment, to repeat it under the same conditions and to base decisions on the clinical context.